Stage III ovarian tumors of low malignant potential (LMP) treated with cisplatin-combination therapy

Sutton, Gregory P.; Bundy, B.; Omura, Go; Yordan, Edgardo; Beecham, Jackson B.

doi:10.1016/0090-8258(89)90894-9

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For serous extra ovarian disease the prognosis is good (10,32) and collected data does not show evidence that adjuvant chemotherapy improves survival (33,34) . There are reports of surgical complete response (25) but also deaths as a complication of treatment (3,25,34) . Our data showed no significant decrease in recurrence or death for those who received adjuvant therapy, but recurrences were only seen in patients who did not receive adjuvant therapy and numbers were small.…”

Section: Discussionmentioning

confidence: 99%

Ovarian tumors of low malignant potential: a retrospective study of 234 patients

Sykes

Quinn

Rome

1997

Int J Gynecol Cancer

View full text Add to dashboard Cite

Two‐hundred and thirty‐four consecutive patients with a histologic diagnosis of low malignant potential (LMP) ovarian tumors between 1972 and 1994 form the basis of this study. Six patients had a synchronous intra‐abdominal or pelvic malignancy and six were considered to have areas of early stromal invasion, these patients being considered separately. The patients ages ranged from 16–93 years. The histologic type was mucinous in 53%, serous in 37%, mixed in 7%, and other in 3%. Ovarian tumors were bilateral in 15% with mucinous and 39% with serous disease. Fourteen patients had pseudomyxoma peritonei. Extra ovarian disease was found in 28 (34%) patients with serous and 15 (13%) with mucinous tumors. Five (6%) patients with serous tumors had invasive implants and four had lymph node implants. Clinically 175 patients had stage I disease, 19 had stage II and 28 stage III disease but only 88 patients were formally staged. Follow‐up details were available for 173 (74%) patients, ranging from 2 months to 20 years, mean 54 months. Thirteen patients (6%) died of disease, of whom six had pseudomyxoma peritonei. Twelve patients (6%) had developed invasive malignancy of whom seven died. None of the patients with formally staged Ia or Ib disease had a recurrence. With the exception of patients with synchronous malignancy or pseudomyxoma peritonei the prognosis is good. Surgical staging offers limited prognostic information but sacrifice of fertility is not justified. Adjuvant therapy is not indicated in early stage disease and its role for patients with extra ovarian disease remains controversial.

show abstract

Section: Discussionmentioning

confidence: 99%

Ovarian tumors of low malignant potential: a retrospective study of 234 patients

Sykes

Quinn

Rome

1997

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…As survival of Stage 1 disease is so high following surgery alone (99.3% in our series), no adjuvant therapy could realistically demonstrate a survival advantage. Even for Stage 3 disease little evidence exists that adjuvant chemotherapy is beneficial (1,5,12,15). In one study (I).…”

Section: Discussionmentioning

confidence: 99%

“…Despite the lack of evidence that adjuvant Chemotherapy improves survival in patients with extra-ovarian spread. adjuvant platinum-based chemotherapy continues to be offered in this context (2,7,15). However, of note, the National Institute of Health (NIH) published a consensus statement in 1995 that does not support a role for adjuvant chemotherapy in the management of LMP tumours ( 16).…”

Section: Discussionmentioning

confidence: 99%

Low Malignant Potential Ovarian Tumours: A Review of 175 Consecutive Cases

Buttini

Nicklin

Crandon

1997

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

Epithelial ovarian tumours of low malignant potential (LMP) are known to have a generally good prognosis, although there is not universal agreement on all aspects of treatment. We report a series of 175 patients with LMP ovarian tumours referred to the Queensland Centre for Gynaecological Cancer between January, 1982 and December, 1993. Stage I disease accounted for 142 cases, with only 1 patient dead from disease at 293 months. Twenty nine patients in this group had conservative surgery with 1 recurrence only (in the contralateral ovary) giving a recurrence rate of 3.5%. Survival and treatment data for other stages are presented, and the current literature reviewed. It is suggested that early stage disease may be treated conservatively depending upon the patient's desire to retain reproductive capacity. While adjuvant therapy is not recommended, long-term follow-up is indicated. More advanced disease should be debulked to the smallest practical volume. The role of lymphadenectomy has been questioned, as survival has not been shown to be affected by treatment decisions made as a result of knowing the lymph node status. Whilst some centres give platinum-based adjuvant therapy, the evidence that it is beneficial is not supported by any prospective randomized trials.

show abstract

“…17 Although there was no difference in PFS or OS between the 2 arms, the investigators were able to define several prognostic variables for survival: residual disease (some vs. none), grade (1 vs. 2 or 3), age ( >30 y), and clear-cell carcinoma. Three additional publications include data from GOG 52 with the following results: there is no role for adjuvant chemotherapy for borderline tumors, 21 the benefit from the addition of doxorubicin to CP in *IP chemotherapy protocols are in Table 5. GOG protocols 182, 218, 262 include optimal and suboptimal patients.…”

Section: Optimal Advanced Epithelial Ovarian Cancermentioning

confidence: 98%

“…There was no difference in PFS or OS; however, patients on the C. parvum arm experienced more adverse events (Tables 4 and 5). 16 GOG 52 17,[21][22][23] Although cisplatin was being evaluated in suboptimal patients (GOG 47), GOG 52 assessed cisplatin's role in the ''optimally'' cytoreduced cohort. In the process, GOG 52 (1981 to 1985) defined a new GOG standard for optimal residual disease, r1 cm maximum diameter.…”

Section: Optimal Advanced Epithelial Ovarian Cancermentioning

confidence: 99%

Evolution of the Gynecologic Oncology Group Protocols in the Treatment of Epithelial Ovarian Cancer

Seamon

Richardson

2012

Clinical Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

Stage III ovarian tumors of low malignant potential (LMP) treated with cisplatin-combination therapy

Cited by 3 publications

References 0 publications

Ovarian tumors of low malignant potential: a retrospective study of 234 patients

Ovarian tumors of low malignant potential: a retrospective study of 234 patients

Low Malignant Potential Ovarian Tumours: A Review of 175 Consecutive Cases

Evolution of the Gynecologic Oncology Group Protocols in the Treatment of Epithelial Ovarian Cancer

Contact Info

Product

Resources

About